U.S., March 21 -- ClinicalTrials.gov registry received information related to the study (NCT06886126) titled 'Phase II Clinical Study of HDM1005 Injection in Obese Adults Without Diabetes Mellitus' on Feb. 12.
Brief Summary: It is a multicenter, randomized, double-blind, placebo-controlled phase II clinical trial to evaluate the efficacy and safety of HDM1005 injection in nondiabetic obese adults.
Study Start Date: Feb. 07
Study Type: INTERVENTIONAL
Condition:
Obesity
Intervention:
DRUG: HDM1005 injection or placebo
HDM1005 injection subcutaneous injection QW for 22weeks
Recruitment Status: RECRUITING
Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Published by HT Digital Content Services with permission from Health D...